Next Article in Journal
Isolation and Antibiotic Resistant Research of Tetragenococcus halophilus from Xuanwei Ham, A China High-Salt-Fermented Meat Products
Previous Article in Journal
Characterization of a Carbapenem-Resistant Kluyvera Cryocrescens Isolate Carrying Blandm-1 from Hospital Sewage
Case Report

Frequent Klebsiella pneumoniae Urinary Tract Infections in a Patient Treated with Ruxolitinib

1
Division of Nephrology, Department of Medicine UCLA, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
2
Division of Nephrology, Department of Medicine, UCI School of Medicine, Irvine, CA 92868, USA
3
Division of Nephrology, Department of Medicine, Brigham Women’s and Children’s Hospital, Boston, MA 02101, USA
*
Author to whom correspondence should be addressed.
Received: 12 August 2019 / Revised: 4 September 2019 / Accepted: 11 September 2019 / Published: 16 September 2019
Ruxolitinib is a targeted agent that inhibits Janus 2 Kinase and is approved for use in Polycythemia Vera and Primary Myelofibrosis. Its mechanism of action involves inhibition of cellular proliferation via the Janus kinase/signal transducer and activator of transcription proteins pathway. Ruxolitinib has different immune modulating effects that result in functional immunosuppression, leading to an increased susceptibility to certain infections. Klebsiella pneumoniae infections, in particular, were common among the reported pathogens contracted by ruxolitinib users. We report a 75-year-old male patient who had recurrent K. pneumoniae urinary tract infections while on ruxolitinib for Polycythemia Vera. This case is reported to add to the literature describing an increased susceptibility of patients to this often-resistant bacteria and to raise awareness about the immune modulating effects of JAK inhibitors. View Full-Text
Keywords: Ruxolitinib; Klebsiella pneumonia; Immunemodulation; JAK kinase (Janus Kinase); STAT (Signal Transducer and Activator of Transcription proteins) kinase Ruxolitinib; Klebsiella pneumonia; Immunemodulation; JAK kinase (Janus Kinase); STAT (Signal Transducer and Activator of Transcription proteins) kinase
Show Figures

Figure 1

MDPI and ACS Style

Hanna, R.M.; Khalid, M.; El-Nour, L.A.; Selamet, U. Frequent Klebsiella pneumoniae Urinary Tract Infections in a Patient Treated with Ruxolitinib. Antibiotics 2019, 8, 150. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics8030150

AMA Style

Hanna RM, Khalid M, El-Nour LA, Selamet U. Frequent Klebsiella pneumoniae Urinary Tract Infections in a Patient Treated with Ruxolitinib. Antibiotics. 2019; 8(3):150. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics8030150

Chicago/Turabian Style

Hanna, Ramy M.; Khalid, Maham; El-Nour, Lama A.; Selamet, Umut. 2019. "Frequent Klebsiella pneumoniae Urinary Tract Infections in a Patient Treated with Ruxolitinib" Antibiotics 8, no. 3: 150. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics8030150

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop